Login / Signup
SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-β/Smad pathway.
Chenxue Qi
Mengmeng Lyu
Zhipeng Yao
Fan Zhang
Yan Zhu
Min Qi
Xiaoxiang Cao
Congzhu Li
Hongping Xia
Dongfang Dai
Published in:
Gynecologic oncology (2024)
SVIL highly expressed in the hypoxic microenvironment can increase ovarian cancer progression and cisplatin resistance by activating TGFβ1/smad2/3 pathway. Our study demonstrated that SVIL may be a novel target for the treatment of ovarian cancer.
Keyphrases
</>
transforming growth factor
epithelial mesenchymal transition
signaling pathway
stem cells
combination therapy